$TNDM News

Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

Deutsche Bank Initiates Coverage On Tandem Diabetes Care with Hold Rating, Announces Price Target of $15.5

Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

How The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst Targets

Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?

Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

Tandem Diabetes Care Receives CE Mark For Expanded Indications Of Its Automated Insulin Delivery Systems In Europe

Wells Fargo Upgrade Highlights Tandem Diabetes Care Pharmacy And Pump Shift

Why Is Tandem Diabetes (TNDM) Stock Soaring Today

Wells Fargo Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $27

Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17

Tandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed?

Tandem Diabetes’s Q1 Earnings Call: Our Top 5 Analyst Questions

B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25

Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today

Benchmark Initiates Coverage On Tandem Diabetes Care with Hold Rating

Tandem Diabetes Care, Inc. 2026 Q1 - Results - Earnings Call Presentation

Truist Securities Reiterates Buy on Tandem Diabetes Care, Lowers Price Target to $31

Barclays Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $55